Loading patent…
AssigneeGenmab A/S
InventorsJan Van De Winkel, Paul Parren, Willem Karel Bleeker, Klaus Edvardsen, Jeroen Lammerts Van Bueren, Thomas Valerius, Michael Dechant, Wencke Weisner, Sven Berger
Estimating the term…
The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.
An isolated monoclonal antibody, or an antigen binding portion thereof, which binds to EGFR and comprising the CDR1, CDR2, and CDR3 sequences of the heavy and light chain variable region sequences set forth in SEQ ID NOs:
An isolated monoclonal antibody, or an antigen binding portion thereof, which binds to EGFR and comprising the heavy and light chain variable region sequences set forth in SEQ ID NOs:
Dependencies are inferred from the claim text.